311 related articles for article (PubMed ID: 19672997)
1. Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer.
Du XL; Xia R; Liu CC; Cormier JN; Xing Y; Hardy D; Chan W; Burau K
Cancer; 2009 Nov; 115(22):5296-308. PubMed ID: 19672997
[TBL] [Abstract][Full Text] [Related]
2. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
Pinder MC; Duan Z; Goodwin JS; Hortobagyi GN; Giordano SH
J Clin Oncol; 2007 Sep; 25(25):3808-15. PubMed ID: 17664460
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study.
Doyle JJ; Neugut AI; Jacobson JS; Grann VR; Hershman DL
J Clin Oncol; 2005 Dec; 23(34):8597-605. PubMed ID: 16314622
[TBL] [Abstract][Full Text] [Related]
4. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer.
Hooning MJ; Botma A; Aleman BM; Baaijens MH; Bartelink H; Klijn JG; Taylor CW; van Leeuwen FE
J Natl Cancer Inst; 2007 Mar; 99(5):365-75. PubMed ID: 17341728
[TBL] [Abstract][Full Text] [Related]
5. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
[TBL] [Abstract][Full Text] [Related]
6. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
Jensen BV
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
[TBL] [Abstract][Full Text] [Related]
7. Cardiac mortality in patients with stage I and II diffuse large B-cell lymphoma treated with and without radiation: a surveillance, epidemiology, and end-results analysis.
Pugh TJ; Ballonoff A; Rusthoven KE; McCammon R; Kavanagh B; Newman F; Rabinovitch R
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):845-9. PubMed ID: 19515509
[TBL] [Abstract][Full Text] [Related]
8. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk.
Patt DA; Duan Z; Fang S; Hortobagyi GN; Giordano SH
J Clin Oncol; 2007 Sep; 25(25):3871-6. PubMed ID: 17664457
[TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
10. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
[TBL] [Abstract][Full Text] [Related]
11. Risk of dementia in older breast cancer survivors: a population-based cohort study of the association with adjuvant chemotherapy.
Baxter NN; Durham SB; Phillips KA; Habermann EB; Virning BA
J Am Geriatr Soc; 2009 Mar; 57(3):403-11. PubMed ID: 19278395
[TBL] [Abstract][Full Text] [Related]
12. Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy.
Hurria A; Brogan K; Panageas KS; Pearce C; Norton L; Jakubowski A; Zauderer M; Howard J; Hudis C
Breast Cancer Res Treat; 2005 Jul; 92(2):151-6. PubMed ID: 15986124
[TBL] [Abstract][Full Text] [Related]
13. Cardiac morbidity of adjuvant radiotherapy for breast cancer.
Patt DA; Goodwin JS; Kuo YF; Freeman JL; Zhang DD; Buchholz TA; Hortobagyi GN; Giordano SH
J Clin Oncol; 2005 Oct; 23(30):7475-82. PubMed ID: 16157933
[TBL] [Abstract][Full Text] [Related]
14. [Risk of cardiotoxicity of combination treatment radiotherapy and chemotherapy of locally advanced breast carcinoma stage III].
Bustová I
Klin Onkol; 2009; 22(1):17-21. PubMed ID: 19534435
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma.
Hershman DL; McBride RB; Eisenberger A; Tsai WY; Grann VR; Jacobson JS
J Clin Oncol; 2008 Jul; 26(19):3159-65. PubMed ID: 18591554
[TBL] [Abstract][Full Text] [Related]
16. The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines.
Dranitsaris G; Rayson D; Vincent M; Chang J; Gelmon K; Sandor D; Reardon G
Breast Cancer Res Treat; 2008 Feb; 107(3):443-50. PubMed ID: 17978870
[TBL] [Abstract][Full Text] [Related]
17. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
18. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
Gennari A; Sormani MP; Pronzato P; Puntoni M; Colozza M; Pfeffer U; Bruzzi P
J Natl Cancer Inst; 2008 Jan; 100(1):14-20. PubMed ID: 18159072
[TBL] [Abstract][Full Text] [Related]
19. Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998-2005.
Du XL; Xia R; Burau K; Liu CC
Med Oncol; 2011 Dec; 28 Suppl 1():S80-90. PubMed ID: 20967512
[TBL] [Abstract][Full Text] [Related]
20. Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study.
Schaapveld M; Visser O; Louwman MJ; de Vries EG; Willemse PH; Otter R; van der Graaf WT; Coebergh JW; van Leeuwen FE
J Clin Oncol; 2008 Mar; 26(8):1239-46. PubMed ID: 18323547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
